1 Oral: First Clinical Results from A Phase 1 Trial of PRT3789, a First-in-Class Intravenous SMARCA2 Degrader, in Patients with Advanced Solid Tumors with a SMARCA4 Mutation

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2024-10, Vol.211, p.114530, Article 114530
Main Authors: Yap, T.A., Dowlati, A., Dagogo-Jack, I., Vibert, J., Spira, A.I., Garcia, V. Moreno, Punekar, S.R., Calvo, E., Sonpavde, G.P., Awad, M., Riess, J.W., Hernández-Guerrero, T., Herzberg, B., Italiano, A., Swalduz, A., LoRusso, P., Smit, E.F., Garon, E.B., Novotny, W., Guo, R.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0959-8049
DOI:10.1016/j.ejca.2024.114530